Thrive Capital Management (Pennsylvania)’s West Pharmaceutical WST Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-956	Closed	-$214K	–	190
2025 Q1	$214K	Buy	+956	New	+$263K	0.13%	110
2024 Q4	–	Sell	-965	Closed	-$290K	–	178
2024 Q3	$290K	Hold	965	–	–	0.14%	155
2024 Q2	$318K	Hold	965	–	–	0.15%	154
2024 Q1	$382K	Hold	965	–	–	0.2%	66
2023 Q4	$340K	Sell	965 -6	-0.6%	-$2.12K	0.18%	89
2023 Q3	$364K	Hold	971	–	–	0.2%	81
2023 Q2	$371K	Buy	971 +9	+0.9%	+$3.21K	0.21%	82
2023 Q1	$328K	Hold	962	–	–	0.21%	82
2022 Q4	$226K	Hold	962	–	–	0.15%	105
2022 Q3	$237K	Hold	962	–	–	0.16%	98
2022 Q2	$291K	Sell	962 -10	-1%	-$3.25K	0.2%	80
2022 Q1	$399K	Buy	972 +10	+1%	+$3.92K	0.24%	60
2021 Q4	$451K	Buy	+962	New	+$414K	0.29%	69
2021 Q3	–	Sell	-962	Closed	-$345K	–	110
2021 Q2	$345K	Hold	962	–	–	0.27%	89
2021 Q1	$271K	Hold	962	–	–	0.25%	99
2020 Q4	$273K	Buy	+962	New	+$270K	0.29%	69

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Thrive Capital Management (Pennsylvania)'s WST Position: Q2 2025 in Review

Thrive Capital Management (Pennsylvania) sold out of West Pharmaceutical (WST) in Q2 2025, closing a stake of 956 shares — an estimated $214K sold.

Thrive Capital Management (Pennsylvania) first reported a position in WST in Q4 2020 and held it in 16 quarters. The position peaked at $451K in Q4 2021. 730 funds tracked by Wall St. Rank hold WST as of Q2 2025.

Thrive Capital Management (Pennsylvania) reported no remaining West Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Thrive Capital Management (Pennsylvania) sold 956 West Pharmaceutical shares in Q2 2025, an estimated $214K.
Thrive Capital Management (Pennsylvania) first reported a position in West Pharmaceutical in Q4 2020 and held it in 16 quarters.
Thrive Capital Management (Pennsylvania)'s West Pharmaceutical position peaked at $451K in Q4 2021.
730 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2025.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q2 2025, filed 8 Aug 2025.